Here, we present an integrated workflow to identify phenotypic and molecular features that characterize circulating tumor cells (CTCs). We combine live immunostaining and robotic micromanipulation of single and clustered CTCs with single cell-based techniques for downstream analysis and assessment of metastasis-seeding ability.
Blood-borne metastasis accounts for most cancer-related deaths and involves circulating tumor cells (CTCs) that are successful in establishing new tumors at distant sites. CTCs are found in the bloodstream of patients as single cells (single CTCs) or as multicellular aggregates (CTC clusters and CTC-white blood cell clusters), with the latter displaying a higher metastatic ability. Beyond enumeration, phenotypic and molecular analysis is extraordinarily important to dissect CTC biology and to identify actionable vulnerabilities. Here, we provide a detailed description of a workflow that includes CTC immunostaining and micromanipulation, ex vivo culture to assess proliferative and survival capabilities of individual cells, and in vivo metastasis-formation assays. Additionally, we provide a protocol to achieve the dissociation of CTC clusters into individual cells and the investigation of intra-cluster heterogeneity. With these approaches, for instance, we precisely quantify survival and proliferative potential of single CTCs and individual cells within CTC clusters, leading us to the observation that cells within clusters display better survival and proliferation in ex vivo cultures compared to single CTCs. Overall, our workflow offers a platform to dissect the characteristics of CTCs at the single cell level, aiming towards the identification of metastasis-relevant pathways and a better understanding of CTC biology.
The clinical manifestation of metastasis in distant organs represents the final stage of cancer progression and accounts for more than 90% of cancer-related deaths1. The transition from localized to metastatic disease is a multi-step process, often mediated by circulating tumor cells (CTCs)2,3,4. These cells are shed from the primary tumor into the blood circulation and are transported to distant organs, where they may extravasate and establish metastatic lesions5,6. Although solid tumors can release a relatively high number of CTCs, most CTCs are destined to die, owing to high shear forces in circulation, anoikis-mediated cell death, immune attack or limited capabilities to adapt to a foreign microenvironment7. Therefore, it is pivotal to establish tools that enable the dissection of the molecular features of those CTCs that are endowed with metastasis-seeding ability. Recent preclinical and clinical studies suggest that the presence and quantity of single CTCs and CTC clusters is associated with a worse outcome in patients with various types of solid tumors8,9,10,11,12,13,14. CTC clusters are groups of two or more CTCs attached to each other during circulation and are more efficient in forming metastasis compared to single CTCs3,15,16. Cells within a cluster maintain strong cell-cell adhesion through desmosomes and adherens junctions, which may help to overcome anoikis17,18. Recently, we observed that clustering of CTCs is linked to hypomethylation of binding sites for stemness- and proliferation-associated transcription factors, leading to an increased ability to successfully initiate metastasis19. CTC cluster dissociation results in remodeling of key binding sites, and consequently, the suppression of their metastatic potential19. Additionally to clusters of cancer cells, CTCs can also associate to white blood cell (most frequently neutrophils) to maintain high proliferation levels in circulation and increase their metastatic capability20. However, the biology of CTCs is understood only in part and several questions remain open, including the underlying molecular features and vulnerabilities of single and clustered cells.
In recent years, several strategies have been established that exploit cell-surface expression patterns as well as physical properties of CTCs for their isolation21,22,23,24,25. Antigen-dependent isolation methods rely mostly on the expression of cell surface Epithelial Cell Adhesion Molecule (EpCAM)26. The most frequently used and (at present) the only FDA-approved platform for CTC enumeration, is the CellSearch system, which is based on a two-step procedure to isolate CTCs21. In the first step, plasma components are removed by centrifugation, while CTCs are captured with magnetic ferrofluids coupled to anti-EpCAM antibodies. In the second step, the CTC-enriched solution is stained for nucleated (DAPI-positive) cells expressing cytokeratin (CK)8,18,19, while white blood cells (WBCs) are identified using the pan-leukocyte marker CD45. Finally, captured cells are placed on an integrated screening platform and CTCs are identified through the expression of EpCAM, CKs, and DAPI while being negative for CD45. Although this is considered to be the gold standard for CTC enumeration, downstream molecular analysis is challenging with this technology due to inherent constraints in CTC retrieval. Additionally, given its isolation procedure, CellSearch may favor the enrichment of CTCs with higher EpCAM levels compared to CTCs with lower EpCAM expression, due for instance to cancer heterogeneity27 or downregulation of epithelial markers28,29. To overcome these limitations, antigen-independent technologies for the enrichment of CTCs have emerged. For example, the CTC-iChip integrates hydrodynamic separation of nucleated cells, including CTCs and WBCs from remaining blood components, followed by an immunomagnetic depletion of antibody-tagged WBCs, allowing purification of untagged and viable CTCs in solution25. Additionally, the fact that most CTCs are slightly bigger than red blood cells (RBCs) or WBCs led to the development of size-based CTC enrichment technologies23,30 (e.g., the Parsortix system (ANGLE)) which makes use of a microfluidic-based technology, comprising a narrowing channel across the separation cassette, leading cells to a terminal gap of either 10, 8, 6.5 or 4.5 µm (different sizes are available depending upon the expected diameter of target cancer cells). Most of the blood cells pass through the narrow gap, while CTCs get trapped due to their size (but also due to their lower deformability) and are, therefore, retained in the cassette. Reverting the flow direction enables the release of captured CTCs, which are in a viable state and suitable for downstream analysis. Independently of the chosen protocol for CTC isolation, however, typical post-enrichment procedures still yield CTCs that are mixed with a relatively small number of RBCs and WBCs, making the analysis of pure single or bulk CTCs challenging. To address this issue, we established a workflow that allows CTC manipulation without potential bias introduced by blood cell contaminants. The addition of immunostaining beforehand, with variable antibody-combinations, distinguishes CTCs from blood cells and even allows to identify CTC subgroups with distinct surface-marker expression profiles. This highly customizable procedure can be then further combined with specific downstream applications.
Here, we describe a workflow that starts from a CTC-enriched product (obtained with any CTC enrichment technology of choice) and combines several approaches to gain insight into CTC biology at single-cell resolution. In a nutshell, our workflow enables the identification of single CTCs, CTC clusters and CTC-WBC clusters by live immunostaining, followed by single-cell micromanipulation and downstream analysis using ex vivo culturing protocols, single cell sequencing, and in vivo metastasis assays.
All the procedures involving blood samples from patients were performed upon signed informed consent of the participants. Procedures were run according to protocols EKNZ BASEC 2016-00067 and EK 321/10, approved by the ethical and institutional review board (Ethics Committee northwest/central Switzerland [EKNZ]), and in compliance with the Declaration of Helsinki.
All the procedures concerning animals were performed in compliance with institutional and cantonal guidelines (approved mouse protocol #2781, Cantonal Veterinary Office of Basel-City).
1. Patient sample preparation
2. Mouse sample preparation
3. CTCs live immunostaining
4. Micromanipulation of CTCs and single-cell picking
NOTE: Before starting, be aware that the micromanipulator requires up to 45 min for complete set up. Once set up, the procedure for CTC identification and micromanipulation requires up to 2 minutes per cell (or cluster).
5. Single-cell picking and seeding for survival and proliferation analysis
6.CTC cluster breaking and single-cell picking for sequencing
7. CTCs isolation for mouse injection
The presented workflow allows the preparation of individual CTCs, either from single CTCs or separated from CTC clusters. CTCs from patients or tumor-bearing mice are enriched from whole blood with available CTC-enrichment methods and then stained with antibodies against cancer-associated markers (e.g., EpCAM, green) and WBC-specific markers (e.g., CD45, red) (Figure 1A). The stained CTC product is then transferred to the micromanipulation station were individual cells are picked, deposited in PCR tubes or multiwell plates and prepared for downstream analysis, including single-cell sequencing, in vitro culture or in vivo assays (Figure 1B).
Reliability of this method is based on a proper target-cell distinction during manual cell picking. Live immunostaining with anti-EpCAM antibodies visualizes cancer cells in the suspension and enables an accurate distinction from CD45-positive events (most likely, WBCs) (Figure 2A). When properly calibrated and maintained, CellCelector provides well-controlled cell manipulation. Precise CTC isolation is characterized by aspiration of only the desired target without surrounding contaminant cells (RBCs or WBCs), as shown on the pictures taken before and after CTC cluster aspiration (Figure 2B, C).
As previously described, CTC clusters display a more metastatic phenotype when compared to matched single CTCs19. Yet, whether the presence of neighboring cells is sufficient to increase the proliferation rate of cells within clusters is unknown. In order to address this question, 1009 single CTC and 1008 CTC clusters ranging between 2-17 cells (with 89.5% of them being 2-5 cell clusters) derived from the CTC-derived BR16 cell line20 were micromanipulated into individual wells of 384-well ultra-low attachment plates. The number of live cells in every well was counted manually under the microscope and recorded weekly. All analyses were performed after normalization of cell number (i.e., the three-cell cluster was analyzed as three individual cells). Unsuccessful colonies were characterized by the lack of living cells in the well at the end of the experiment. As suspected, CTC clusters showed increased survival compared to single CTCs and gave rise to cell colonies within 56 days of in vitro culturing (Figure 3A, 3B). Notably, CTC clusters also showed higher proliferation rate and thus reached higher final cell numbers (Figure 3C), indicating that direct contact with other tumor cells has an impact on both their viability and proliferation rate.
Lastly, we provide single-cell RNA sequencing data of CTCs directly isolated from breast cancer patients. Particularly, we show a t-Distributed Stochastic Neighbor Embedding (tSNE) of single cells derived from either single CTCs, CTC clusters or CTC-WBC clusters (Figure 4). This approach allows the identification of cells with similar gene expression profile, as well as the distinction of cell populations that differ based on the expression of particular genes.
Figure 1. Schematic representation of the experimental workflow. (A) CTCs are obtained from the blood of cancer patients or mouse cancer models, enriched using available methods and labeled with antibodies to discriminate tumor cells (green) from white blood cells (red). (B) Precise micromanipulation of CTCs facilitates multiple procedures and applications e.g., single-cell sequencing, CTC culture or in vivo transplantation experiments. Please click here to view a larger version of this figure.
Figure 2. Representative pictures of CTCs before and after micromanipulation. (A) Representative images of CTCs derived from a CTC-derived xenograft (NSG-CDX-BR16) and stained with antibodies anti-EpCAM (green) and anti-CD45 (red) to enable the visualization of CTCs and white blood cells, respectively. Magnification 40x is shown. (B,C) Micromanipulation allows for the precise separation of CTCs from unwanted cells as shown in the images before (left) and after (right) cell-aspiration procedure. Magnification 10x. The larger field of view (B) and narrower field of view (C) are shown, respectively. Please click here to view a larger version of this figure.
Figure 3. Survival and proliferation analysis of single CTCs and CTC clusters. Individual cells from single CTCs or CTC clusters from cultured CTC-derived BR16 cells were micromanipulated into 384-well plates. (A) Kaplan-Meier plot showing the survival probability of seeded single cells versus cell clusters. P<0.0001 by pairwise Log-Rank test. (B) Bar graph representing the proportion of colonies that consisted of live cells at the end of the experiment (day 56). P<0.0001 by chi-square test. (C) Heatmaps visualizing normalized cell number distribution over the course of the experiment (day 0, 8, 32, 56). Each block represents one starting cell and the heatmap shows the number of cells per well at a given timepoint. d=day. Please click here to view a larger version of this figure.
Figure 4. Single-cell RNA sequencing. Visualization of CTC RNA expression data using t-Distributed Stochastic Neighbor Embedding (tSNE). Each dot represents a single cell derived from a single CTC, a CTC cluster or a CTC-WBC cluster. Colors of the dots correspond to the donor ID. Please click here to view a larger version of this figure.
The molecular characterization of CTCs holds the promise to improve our understanding of the metastatic process and guide the development of new anti-metastasis therapies. Here we provide a detailed description of those protocols that enable CTC micromanipulation and downstream analysis, including both single cell-based functional assays, gene expression analysis and in vivo transplantation for metastatic potential assessment20.
Among the most critical steps of our protocol, micromanipulation of CTC-enriched products aims at gaining single cell resolution from relatively heterogeneous cell suspensions, i.e. allowing to reach the highest levels of purity and to improve the quality of subsequent functional or molecular analyses. For example, single cell picking of CTCs has enabled us and others to investigate CTC heterogeneity (e.g., differences between single CTCs, CTC clusters, and CTC-WBC clusters), both from a molecular standpoint and from the perspective of being able to assess metastasis-initiation capability. While we generally favor cell picking protocols that allow the experimenter to manually isolate CTCs (i.e. allowing for a higher degree of flexibility depending on the characteristics of individual targets), automated solutions are now available to facilitate cell picking and to accelerate the CTC isolation process in well-controlled experiments.
When considering single cell micromanipulation in the context of CTC analysis, time is a very critical limiting factor. Since our protocol is meant to be conducted on living cells, it is imperative to proceed as fast as possible to minimize changes due to the ex vivo environment, such as the upregulation or downregulation of genes that are context-dependent. When compared to the existing techniques for CTC analysis, single cell micromanipulation of live CTCs offers higher flexibility for the downstream analysis of choice, ranging from single cell sequencing to direct functional assays.
In this manuscript, we also provide new data that highlight important differences between single and clustered CTCs by micromanipulating and seeding more than thousand single CTCs or CTC clusters (with a clearly defined size) from a CTC-derived cell line in individual wells of a microtiter plate. First, we observe that CTC clusters (i.e., the presence of neighboring cells) are sufficient to achieve better survival rates of seeded cells, supporting our in vivo data suggesting lower apoptotic rates of CTC clusters upon seeding at a distant site19. Further, even upon normalization for the number of seeded cells, cancer cells grown as clusters display much higher proliferation rates, further reinforcing the concept that clustered CTCs are highly efficient metastasis contributors.
Together, we present specific protocols for CTC analysis with the purpose to promote single cell-related investigations in the CTC field. In the future, we anticipate that these protocols might be useful for CTC-related investigations, aiming towards a better understanding of the biology that characterizes blood-borne metastasis in various cancer types.
The authors have nothing to disclose.
We thank all patients that donated blood for our study, as well as all involved clinicians and study nurses. We thank Jens Eberhardt, Uwe Birke, and Dr. Katharina Uhlig from ALS Automated Lab solutions GmbH for continuous support. We thank all members of the Aceto lab for feedback and discussions. Research in the Aceto lab is supported by the European Research Council, the European Union, the Swiss National Science Foundation, the Swiss Cancer League, the Basel Cancer League, the two Cantons of Basel through the ETH Zürich, and the University of Basel.
Anti-human EpCAM-AF488 | Cell Signaling Technology | CST5198 | clone: VU1D9 |
1X DPBS | Invitrogen | 14190169 | no calcium, no magnisium |
6-wells Ultra-low attachment plate | Corning | 3471 | |
Anti-human CD45-BV605 | Biolegend | 304041 | clone: HI30 |
Anti-human EGFR-FITC | GeneTex | GTX11400 | clone: ICR10 |
Anti-human HER2-AF488 | Biolegend | 324410 | clone: 24D2 |
Anti-mouse CD45-BV605 | Biolegend | 103139 | clone: 30-F11 |
BD Vacutainer K2EDTA | BD | 366643 | for human blood collection |
Cell Celector | ALS | CC1001 | core unit |
CellD software | ALS | version 3.0 | |
Cultrex PathClear Reduced Growth Factor BME, Type 2 | R&D Systems | 3533-005-02 | |
Micro tube 1.3 mL K3EDTA | Sarstedt | 41.3395.005 | for mouse blood collection |
PCR tubes | Corning | PCR-02-L-C | |
RLT Plus | Quiagen | 1053393 | |
SUPERase In RNase Inhibitor | Thermo Fisher | AM2696 | 1 U/µL |